Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
281-300 of 1,694 trials

Nicotinamide for Liver Fibrosis in Type 2 Diabetes

We are studying whether nicotinamide can help slow liver fibrosis in people with type 2 diabetes. The trial will also assess safety and other health factors related to obesity.

Hepatic Fibrosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesDiabetologyEndocrinologyHepatology

Fibrodysplasia Ossificans Progressiva: INCB000928 Study

We are testing a new medication, INCB000928, to see if it can prevent new bone growth in people with Fibrodysplasia Ossificans Progressiva. The study will also evaluate the safety and tolerability of this treatment.

Fibrodysplasia Ossificans Progressiva>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineOrthopedics and Traumatology

Breast Cancer: Stopping CDK4/6 Inhibitors

We are studying whether stopping CDK4/6 inhibitors helps maintain disease stability in patients with metastatic HR positive, HER2 negative breast cancer. This trial involves patients who have had stable disease after long-term treatment.

Metastatic HR Positive, HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Chronic Pancreatitis: Metamizole for Pain Relief

We are investigating whether adding metamizole to existing pain treatments helps reduce pain in patients with chronic pancreatitis diagnosed within the last three years.

Chronic Pancreatitis1-2 yearsMonitoring phase (IV)Standard MedicinesGastroenterologyInternal Medicine

Esophageal Cancer: Preventing Infections After Surgery

We are studying whether a special treatment can reduce the risk of pneumonia and other infections in patients undergoing surgery for esophageal cancer. This may help improve recovery and overall health after the procedure.

Esophageal Cancer3-6 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesGastroenterologyInfectious DiseasesOncologyPulmonology

Alpelisib for Lymphatic Malformations with PIK3CA Mutation

We are studying whether alpelisib can improve symptoms and imaging results in adults and children with lymphatic malformations caused by a PIK3CA mutation. Participants will be compared to those receiving a placebo to assess the treatment's effectiveness.

Lymphangioma>2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Endometrial Cancer: NEPA for Nausea Relief

We are studying whether a single dose of NEPA can effectively prevent nausea and vomiting in patients with endometrial cancer receiving chemotherapy. This trial also assesses the safety of NEPA and its effects on patients' quality of life.

Chemotherapy-Induced Nausea and Vomiting Prophylaxis≤3 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesInternal MedicineOncology

Alzheimer's Disease: KarXT Medication Study

We are examining how well the medication KarXT is tolerated over a long period in people with psychosis related to Alzheimer's disease. This study aims to ensure the safety of this treatment for participants.

Psychosis Associated with Alzheimer's Disease1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPsychiatry

Advanced Ovarian Cancer: Comparing Treatment Combinations

We are studying two different drug combinations to see which one helps patients with advanced ovarian cancer live longer without disease progression after surgery. This trial involves patients who have undergone complete initial surgery.

Advanced Ovarian Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Advanced Breast Cancer: Saruparib and Camizestrant Study

We are studying a new combination treatment for adults with advanced hormone receptor-positive, HER2-negative breast cancer. The goal is to see if it helps patients live longer without disease progression compared to standard therapies.

Advanced Breast CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyOncology

Fertility Treatment: Natural Progesterone vs. GnRH Antagonists

We are comparing a natural progesterone treatment to a standard injectable medication for women undergoing ovarian stimulation. The goal is to see which method is more effective and cost-efficient in preventing hormonal surges.

Women Undergoing Ovarian Stimulation for Oocyte DonationMonitoring phase (IV)No PlaceboInvestigational MedicinesGynecology and Obstetrics

Metastatic Melanoma: Diclofenac with PD-1 Inhibitor

We are studying whether adding diclofenac to ongoing PD-1 inhibitor therapy helps patients with metastatic melanoma who have stable disease. This trial aims to evaluate the potential benefits of this combination treatment.

Metastatic Melanoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesDermatologyOncology

Lumbar Spinal Surgery: Erector Spinae Plane Block

We are studying whether a specific pain management technique can reduce the need for morphine after lumbar spinal surgery. We will also look at recovery quality and any complications related to the procedure.

Patients Undergoing Lumbar ArthrodesisMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOrthopedics and TraumatologyOtolaryngology

Community-Acquired Pneumonia: Customized Antibiotic Duration Study

We are investigating whether a new strategy for shortening antibiotic treatment is as effective as standard care for hospitalized patients with pneumonia. This study aims to improve patient outcomes while reducing unnecessary antibiotic use.

Community-acquired Pneumonia>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal MedicinePulmonology

Prostate Cancer: AZD5305 Treatment Study

We are studying whether AZD5305, combined with standard hormonal treatments, can improve outcomes for men with metastatic castration-sensitive prostate cancer. This trial compares the new treatment to a placebo to assess its effectiveness.

Metastatic Castration-Sensitive Prostate Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Eosinophilic Granulomatosis With Polyangiitis: NS-229 Study

We are testing a new treatment, NS-229, to see if it helps patients with Eosinophilic Granulomatosis With Polyangiitis achieve remission better than a placebo. The study will also look at any side effects and the time until symptoms worsen.

Eosinophilic Granulomatosis with Polyangiitis6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesRheumatology

Neuroblastoma: ABTL0812 Treatment for Children

We are testing a new drug, ABTL0812, in children with relapsed or refractory neuroblastoma and other solid tumors. The study aims to find the best dose and evaluate its safety and effectiveness when used alone or with other therapies.

Relapsed/Refractory Neuroblastoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Advanced Solid Tumors: Rezatapopt Treatment Study

We are evaluating a new treatment for patients with advanced solid tumors that have a specific genetic mutation. The study aims to understand its effectiveness and safety, as well as how it affects quality of life.

Locally Advanced or Metastatic Solid Tumors with TP53 Y220C MutationSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Advanced Solid Tumors: [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452 Study

We are studying the safety and effectiveness of two new treatments for patients with advanced solid tumors that cannot be removed by surgery. This trial also looks at how well these treatments can help in imaging the tumors.

Colorectal CancerDuctal Adenocarcinoma of PancreasClear Cell Renal Cell Carcinoma6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Cancer Treatment Continuation Study

We are offering ongoing treatment for cancer patients who participated in earlier studies. This study checks the safety of the therapy while ensuring patients have access to their treatment.

Cancer Treatment Continuation>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology